首页> 外文期刊>BMC Medical Genetics >Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study
【24h】

Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study

机译:ABO血型SNP rs505922与乳腺癌表型之间的关系:基因型与表型的相关性研究

获取原文
           

摘要

Background To date, evaluation of the association of the ABO blood group and breast cancer has yielded mixed results. SNP rs505922, located within the first intron of the ABO gene, has been associated with the adenocarcinoma subtype of pancreatic cancer. To evaluate the association between genetic variation in the ABO blood group and risk of breast cancer, rs505922 was genotyped in 629 Caucasian women with invasive breast cancer, representing a variety of clinical and pathological tumor types. Methods Genomic DNA was isolated from blood. TaqMan SNP assay C_2253769_10 was used to determine genotypes for each patient at rs505922. Statistical analysis was performed using chi-square analysis using a P-value Results Genotypes were generated for 100% of the 629 patients in this study. Allele and genotype frequencies did not vary significantly for age at diagnosis, tumor stage, size or grade, hormone, HER2 or lymph node status, intrinsic subtype, tumor type or patient outcome. Conclusions Allele frequencies for rs505922 did not differ between women with breast cancer and published HapMap frequencies from women of European descent. Further stratification into different tumor phenotypes also failed to reveal an association between rs505922 and any clinical characteristics. Together, these data suggest that the minor allele of rs505922 and the resulting non-O blood types are not associated with increased risk or less favorable tumor characteristics or prognosis in breast cancer.
机译:背景技术迄今为止,对ABO血型与乳腺癌的关联性的评估产生了不同的结果。位于ABO基因第一个内含子中的SNP rs505922与胰腺癌的腺癌亚型有关。为了评估ABO血型的遗传变异与乳腺癌风险之间的关联,对629位白人患有浸润性乳腺癌的白人女性进行了rs505922基因分型,分别代表各种临床和病理类型的肿瘤。方法从血液中分离基因组DNA。 TaqMan SNP分析C_2253769_10用于确定每个患者在rs505922的基因型。使用P值使用卡方分析进行统计分析。结果本研究中629例患者中有100%产生了基因型。诊断时的年龄,肿瘤分期,大小或等级,激素,HER2或淋巴结状态,内在亚型,肿瘤类型或患者预后等位基因和基因型频率在年龄上无显着变化。结论rs505922的等位基因频率在乳腺癌女性之间没有差异,并且已发表欧洲血统女性的HapMap频率。进一步分为不同的肿瘤表型也未能揭示rs505922与任何临床特征之间的关联。总之,这些数据表明rs505922的次要等位基因和所得的非O血型与乳腺癌的风险增加或较不利的肿瘤特征或预后无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号